articleTop 1% cited

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

Clinical Pharmacology & Therapeutics · 2006 · Vol. 79(1) · pp. 103–113

Sung Eun Sim✉(Karolinska Institutet)Carl Risinger(Karolinska University Hospital)Victor Næstholt Dahl(Karolinska University Hospital)Eleni Aklillu(Karolinska University Hospital)Mette Krogh Christensen(Karolinska Institutet)Leif Bertilsson(Karolinska University Hospital)Magnus Ingelman‐Sundberg(Karolinska University Hospital)

View via DOI Publisher page

Abstract

CYP2C19*17 is likely to cause therapeutic failures in drug treatment with, for example, proton pump inhibitors and antidepressants.

Pharmacogenetics and Drug Metabolism Drug Transport and Resistance Mechanisms Pharmaceutical studies and practicesCYP2C19DrugDrug metabolismPharmacologyPharmacogeneticsMedicineMetabolismChemistryGeneInternal medicine

MeSH terms

AnimalsAnticonvulsantsAntidepressive AgentsAryl Hydrocarbon HydroxylasesChinaEnzyme InhibitorsEthiopiaGene FrequencyGenotypeHumansMixed Function OxygenasesMaleMephenytoinMutationOmeprazole

Citations

723

FWCI

46.76

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update